Skip to main content
Premium Trial:

Request an Annual Quote

Migrations: Mar 6, 2009


Fate Therapeutics announced this week that Dan Shoemaker has been named chief technology officer.

Shoemaker was most recently chief scientific officer of ICx Biosystems. From 2003 to 2005, he was chief scientific officer of GHC Technologies, where he led the research and development of rapid ultrasensitive detection assays for biodefense and clinical point-of-care diagnostics. From 1998 to 2003, Shoemaker held several positions at Merck Research Laboratories, including director of target discovery, senior director at Rosetta Inpharmatics, and research fellow in the department of molecular neurosciences.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.